Lehman & Derafelo Financial Resources LLC grew its stake in shares of CVS Health Corp (NYSE:CVS) by 0.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 111,267 shares of the pharmacy operator’s stock after acquiring an additional 544 shares during the quarter. CVS Health comprises approximately 2.5% of Lehman & Derafelo Financial Resources LLC’s portfolio, making the stock its 7th biggest position. Lehman & Derafelo Financial Resources LLC’s holdings in CVS Health were worth $7,229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently modified their holdings of the company. State of Alaska Department of Revenue boosted its position in shares of CVS Health by 17.9% during the second quarter. State of Alaska Department of Revenue now owns 268,896 shares of the pharmacy operator’s stock valued at $17,469,000 after buying an additional 40,759 shares during the last quarter. Stoneridge Investment Partners LLC boosted its position in shares of CVS Health by 33.8% during the first quarter. Stoneridge Investment Partners LLC now owns 77,805 shares of the pharmacy operator’s stock valued at $4,616,000 after buying an additional 19,647 shares during the last quarter. Symphony Financial Ltd. Co. purchased a new stake in shares of CVS Health during the second quarter valued at $216,000. Artemis Investment Management LLP boosted its position in shares of CVS Health by 10.3% during the first quarter. Artemis Investment Management LLP now owns 895,029 shares of the pharmacy operator’s stock valued at $53,216,000 after buying an additional 83,635 shares during the last quarter. Finally, AJO LP boosted its position in shares of CVS Health by 3,245.8% during the first quarter. AJO LP now owns 1,370,762 shares of the pharmacy operator’s stock valued at $81,326,000 after buying an additional 1,329,792 shares during the last quarter. Hedge funds and other institutional investors own 76.04% of the company’s stock.
CVS stock traded down $1.06 during midday trading on Friday, hitting $62.94. 9,200,682 shares of the company’s stock were exchanged, compared to its average volume of 6,159,701. The business has a 50-day simple moving average of $63.99 and a two-hundred day simple moving average of $64.46. The company has a current ratio of 0.99, a quick ratio of 0.70 and a debt-to-equity ratio of 1.29. The stock has a market capitalization of $83.65 billion, a PE ratio of 11.40, a P/E/G ratio of 1.42 and a beta of 0.76. CVS Health Corp has a 1-year low of $52.04 and a 1-year high of $77.03.
The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Wednesday, July 22nd. CVS Health’s dividend payout ratio is presently 28.25%.
In other CVS Health news, EVP Alan Lotvin purchased 5,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $63.14 per share, for a total transaction of $315,700.00. Following the completion of the purchase, the executive vice president now directly owns 15,161 shares in the company, valued at $957,265.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is owned by company insiders.
CVS has been the topic of several research reports. Credit Suisse Group raised CVS Health from a “neutral” rating to an “outperform” rating and set a $75.00 target price on the stock in a research report on Thursday, May 14th. They noted that the move was a valuation call. Royal Bank of Canada reissued a “buy” rating on shares of CVS Health in a research report on Thursday, July 9th. Robert W. Baird raised their target price on CVS Health from $62.00 to $66.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Citigroup dropped their target price on CVS Health from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, SVB Leerink started coverage on CVS Health in a research note on Wednesday, July 1st. They issued a “market perform” rating and a $72.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. CVS Health presently has a consensus rating of “Buy” and an average target price of $80.35.
CVS Health Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Featured Article: Capital Gains Distribution
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.